Cambridge Cognition Joins Landmark Alzheimer’s Project
Company Announcements

Cambridge Cognition Joins Landmark Alzheimer’s Project

Cambridge Cognition Holdings (GB:COG) has released an update.

Cambridge Cognition Holdings PLC, a developer of digital solutions for brain health assessment, has been awarded an Innovate UK grant to participate in the Bio-Hermes 2 project, which focuses on Alzheimer’s Disease research. Their CANTAB touchscreen and Winterlight voice assessment tools will be used to analyze a large dataset from 1,200 patients over 24 months, aiming to enhance Alzheimer’s drug development. CEO Matthew Stork expresses enthusiasm for the project’s potential to create an integrated assessment solution for Alzheimer’s disease.

For further insights into GB:COG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskCambridge Cognition’s Spin-Out Gains £1M for Drug Development
TipRanks UK Auto-Generated NewsdeskCambridge Cognition Unveils AQUA to Revolutionize Clinical Trials
TipRanks UK Auto-Generated NewsdeskCambridge Cognition Announces Leadership Resignation
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App